The restitution is stipulated in a permanent injunction order the US Federal Trade Commission unveiled recently against a group of companies all doing business under the aegis of Mile High Madison Group, Inc., which is registered in Delaware.
The subsidiary companies, which all also registered in Delaware, are Nordic Clinical, Inc., Encore Plus Solutions, Inc., Le Groupe Mile High Madison, Inc., and Clinique Nordique, Inc. The principals, who were also named in the order, are Vittorio DiCriscio and Vito Proietti.
The pair and their companies marketed a number of dietary supplements, mostly by direct mail, under the names Neurocet, Regenify, and Resetigen-D.
FTC said the companies were found to have made unsubstantiated pain management claims on the products. According to the FTC, the mailers and other ads for Neurocet promised the product could significantly treat pain, including joint, back, arthritis, and headache pain, stiffness, and inflammation, and provide stronger, longer lasting relief than other pain drugs.
According to the complaint, the defendants claimed that Regenify and Resetigen-D were anti-aging cure-alls that could repair cells and treat multiple ailments. The Commission contends that the defendants also deceptively advertised Regenify and Resetigen-D through fake doctor endorsements and fake consumer testimonials. The complaint further alleges that the defendants falsely claimed that Neurocet, Regenify, and Resetigen-D were clinically proven to treat these conditions.